DermTech Publishes Clinical Data in the Journal of American Academy of Dermatology
SAN DIEGO--(BUSINESS WIRE)--DermTech International (“DermTech”), a privately held molecular diagnostics company commercializing non-invasive gene expression tests for dermatology, announced the publication of a paper entitled, “Development of a novel noninvasive adhesive patch test for the evaluation of pigmented lesions of the skin.” The paper, authored by Pedram Gerami, M.D., Associate Professor of Dermatology and Pathology, Department of Dermatology, Northwestern University, can be found at www.jaad.org or on the company’s website www.dermtech.com/publications.
“Development of a novel noninvasive adhesive patch test for the evaluation of pigmented lesions of the skin.”
Clinical diagnosis of skin conditions involves subjective visual assessments that can lead to diagnostic inaccuracies and require surgical biopsies for diagnostic confirmation. DermTech’s non-invasive technology platform provides objective information on gene expression to facilitate clinical diagnosis using tissue samples collected with an adhesive patch rather than a scalpel. The company’s Pigmented Lesion Assay can be used to facilitate the assessment of moles, or nevi, suspicious for melanoma and surgical biopsy procedures.
The Pigmented Lesion Assay demonstrated 89% accuracy in differentiating melanoma from non-melanoma in pigmented skin lesions. Dr. Gerami commented, “We are pleased to publish our study in this high quality peer-reviewed journal. We believe this technology can improve the accuracy of dermatologic diagnosis, improve patient comfort, and lower health care costs.”
Use of Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the expected benefits of DermTech’s technology. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including challenges inherent in developing, manufacturing, and launching new products. These forward-looking statements speak only as of the date hereof and DermTech disclaims any obligation to update these statements.
DermTech is a molecular diagnostics company headquartered in La Jolla, California, that is transforming dermatologic diagnosis through the development of novel gene expression tests to aid the identification of different skin conditions. Our tests analyze skin samples collected non-invasively with an adhesive patch rather than a scalpel. Current dermatologic diagnosis, primarily based on pattern recognition, is subjective, and prone to error. In contrast, DermTech’s tests provide objective, biology-based information that is highly accurate. For additional information visit: www.dermtech.com